Avid Bioservices (NASDAQ:CDMO) issued its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.09), Bloomberg Earnings reports. Avid Bioservices had a negative net margin of 46.62% and a negative return on equity of 52.02%. The business had revenue of $6.82 million during the quarter, compared to analysts’ expectations of $8.95 million.
Avid Bioservices (NASDAQ:CDMO) opened at $2.32 on Wednesday. Avid Bioservices has a 1 year low of $2.24 and a 1 year high of $5.78.
The firm also recently declared a dividend, which will be paid on Monday, April 2nd. Shareholders of record on Monday, March 19th will be given a $0.6563 dividend. The ex-dividend date is Friday, March 16th.
CDMO has been the subject of several recent research reports. Zacks Investment Research raised shares of Avid Bioservices from a “sell” rating to a “hold” rating in a research report on Saturday, November 18th. ValuEngine cut shares of Avid Bioservices from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Noble Financial reissued a “buy” rating on shares of Avid Bioservices in a research report on Tuesday, December 12th. Finally, First Analysis initiated coverage on shares of Avid Bioservices in a research report on Tuesday. They issued an “overweight” rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $10.00.
About Avid Bioservices
Avid Bioservices, Inc, formerly Peregrine Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products.
Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.